Revenue segments as reported by the company.

Product sales

Other revenues

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Acquired in-process research and development

Selling, general and administrative

Other

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Amgen

Amgen, Inc. is a biotechnology company, which engages in the discovery, development, manufacture and marketing of human therapeutics. Its products include the following brands: Aranesp, Aimovig, KANJINTI, EVENITY, AMGEVITA, AVSOLA, BLINCYTO, MVASI, Corlanor, Enbrel, EPOGEN, IMLYGIC, Kyprolis, Neulasta, NEUPOGEN, Nplate, Parsabiv, Prolia, Repatha, Sensipar, Vectibix, Otezla, RIABNI, and XGEVA. The company was founded by William K. Bowes, Jr., Franklin Pitcher Johnson, Jr., George B. Rathmann, and Joseph Rubinfeld on April 8, 1980 and is headquartered in Thousand Oaks, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Amgen reports robust Q4 results, navigates pricing challenges for growth

Amgen's Q4 earnings call highlighted strong performance, innovative products, and strategic acquisitions driving growth. Challenges in pricing strategies and market dynamics require careful navigation. Opportunities in promising data, asset advancements, and access strategies position Amgen for future success.

Amgen reports robust Q1 performance, eyes growth in Asia-Pacific

Amgen's Q1 2023 earnings call highlighted strong performance, innovative R&D focus, and growth in key markets like Asia-Pacific.
Despite challenges with inventory issues and pricing dynamics, the company remains optimistic about long-term growth opportunities and biosimilar competitiveness.
Opportunities lie in addressing complex disorders like obesity, expanding market presence, and driving growth in key product franchises.
Overall, Amgen's strategic focus on performance, international expansion, and pipeline advancements positions the company for sustained growth and innovation.

Amgen reports robust Q2 earnings, eyes growth through strategic acquisitions

Amgen's strong Q2 performance, robust sales growth, and strategic acquisitions position the company for continued success.
While facing challenges in competitive markets and potential legal risks, Amgen's focus on innovation and portfolio expansion presents growth opportunities.
With a solid financial outlook, increased R&D investments, and a focus on shareholder returns, Amgen remains well-positioned for future growth.
Updates on key products, positive trial results, and strategic initiatives underscore Amgen's commitment to advancing healthcare and driving value creation.

Amgen reports revenue and earnings growth, eyes AI for innovation

Amgen's Q3 performance showed revenue and earnings growth, driven by strong global volume and record sales for key medicines. The company's pipeline progress and strategic focus on R&D highlight a commitment to innovation and future growth. While challenges exist around acquisition integration and market competition, Amgen is poised for continued success through the end of the decade and beyond.

Amgen reports record sales in Q4 2023, eyes rare diseases

Amgen's Q4 2023 performance was robust, driven by record sales and strategic acquisitions.
Despite short-term challenges like tax payments impacting cash flow, the company remains confident in its long-term growth trajectory.
Opportunities lie in expanding the rare disease portfolio, advancing R&D initiatives, and exploring new therapeutic areas.
Overall, Amgen's strong financials, diverse pipeline, and focus on innovation position it well for sustained growth and global impact.

Amgen reports strong Q1 growth, eyes new markets and innovations

Amgen's Q1 2024 performance reflects strong sales growth, financial resilience, and continued momentum in key product segments, positioning the company for future success.
Despite challenges in competitive differentiation, product launches, and regulatory complexities, Amgen's strategic strengths in innovation, manufacturing, and market expansion offer a solid foundation for growth.
The company's focus on addressing unmet medical needs, exploring new therapeutic areas, and advancing pipeline candidates underscores its commitment to driving patient impact and capturing market opportunities.
With a robust financial outlook, ongoing Phase III trials, and a proactive approach to product development, Amgen is well-positioned to achieve its revenue targets, drive innovation, and deliver value to shareholders.

Amgen reports strong Q2 earnings, eyes growth in diverse markets

Amgen's Q2 2024 earnings call highlighted robust revenue growth, strong sales performance, and promising pipeline developments across various therapeutic areas.
While facing challenges in market dynamics and product differentiation, Amgen's strategic focus on rare diseases and innovative therapies positions it well for future growth.
With a clear outlook on capital allocation, continued expansion in endocrinology, and opportunities in the obesity market, Amgen remains poised for sustained success.

Amgen reports strong Q3 earnings and outlines growth strategies

Amgen's Q3 2024 earnings call highlighted robust financial performance, progress in pipeline development, and strategic initiatives for future growth. With a strong revenue outlook and focus on innovation, Amgen remains well-positioned in the biopharmaceutical industry.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Amgen, Inc. is a biotechnology company, which engages in the discovery, development, manufacture, and marketing of human therapeutics. It operates through Human Therapeutics segment. The company was founded by William K. Bowes, Jr., Franklin Pitcher Johnson, Jr., George B. Rathmann, and Joseph Rubinfeld on April 8, 1980 and is headquartered in Thousand Oaks, CA.

Archer-Daniels-Midland Company

Aflac

Allegion

Broadcom

Becton, Dickinson and Co.

Dover

Con Ed

Emerson Electric

Gilead Sciences

W.W. Grainger

Johnson & Johnson

Kraft Heinz

Kontoor Brands Inc

LyondellBasell Industries

McDonald's

Microsoft

PepsiCo

Pfizer

Southern Company

T. Rowe Price Group

Trane Technologies plc

Unilever

The start of every month is exciting for all dividend income investors as we look back at the previous month and see how much passive dividend income our portfolios generated.

Dividend Income Update March 2022

Long-Term Clinical Benefit and Prolonged Tumor Response Seen With 40.7% Objective Response Rate No New Safety Signals Observed Longest Follow-Up of Patients Treated With a KRASG12C Inhibitor THOUSAND OAKS, Calif. , April 10, 2022 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced the presentation of long-term efficacy and safety data from the CodeBreaK 100 Phase 1/2 trial in patients with KRAS G12C-mutated advanced non-small cell lung cancer (NSCLC) who received LUMAKRAS® (sotorasib)*.

LUMAKRAS® (SOTORASIB) CODEBREAK 100 STUDY SHOWS TWO-YEAR OVERALL SURVIVAL OF 32.5% IN PATIENTS WITH KRAS G12C-MUTATED ADVANCED NON-SMALL CELL LUNG CANCER

Boeing

General Electric

General Electric was sold. Amgen was purchased. Boeing was purchased in Jacob's account.

Our Family Investments: March Transactions

Best Buy

Conagra Brands

Foot Locker

Kimberly-Clark

Texas Instruments

After the first down quarter since 2020, many across Wall Street are examining the winners and losers for the quarter and shuffling the deck, looking for stocks that have the best upside potential for the second quarter and beyond.

Top Analysts Say 8 Q1 Underperforming Dividend Stocks Could Be Huge Q2 Winners

Jazz Pharmaceuticals

Novocure

They're good picks for very different reasons.

3 Biotech Stocks to Buy in April

National Research Corp

These two dividend stocks are proven safe havens.

2 Top Dividend Stocks for 2022

Caterpillar

Celsius Holdings

Chevron

Enphase Energy

Home Depot

Intrepid Potash

Coca-Cola

Loop Industries

Merck

Ouster, Inc

Procter & Gamble

Trillium Therapeutics

Travelers

Walmart

Two sample Breakout Stocks for Week 13 with better than 10% short-term upside potential and a Dow stock pick.

Week 13 MDA Breakout Stocks - April 2022: Short-Term Picks To Give You An Edge

New data further reinforces clinical benefit of Otezla in mild to moderate plaque psoriasis and in patients with palmoplantar pustulosis Real-world evidence data being presented demonstrates continued burden of disease for patients with mild to moderate plaque psoriasis Otezla is the first and only oral therapy FDA approved in adult patients with plaque psoriasis across all severities, including mild, moderate and severe THOUSAND OAKS, Calif. , March 25, 2022 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced that new Otezla (apremilast) data, along with findings on the unmet need for patients with plaque psoriasis, will be presented at the American Academy of Dermatology (AAD) congress in Boston, Massachusetts, March 25-29, 2022.

AMGEN ANNOUNCES NEW OTEZLA (APREMILAST) DATA AT AAD CONGRESS 2022

Amgen's (AMGN) key drugs like Prolia, Repatha, Xgeva and biosimilars are driving sales. Amgen is also rapidly advancing its robust pipeline of early and late-stage assets.

Amgen (AMGN) Outperforms Industry This Year So Far: What Next?

AbbVie

They all have attractive dividends and solid businesses.

3 Dividend Stocks That We'd Buy Without Any Hesitation

The recent market sell-off has encouraged me to focus on blue-chip companies that have a strong track record of delivering shareholder value regardless of the conditions. Amgen fits the description.

Healthy Dividends: Amgen's Growth Makes It A 'Top Idea' And Reinforces Its Position In My Dividend Portfolio

Amgen's share price has traded in a $220 +/- 10% window since late 2019, with the exception of the COVID-19 flash crash.

Amgen: Long-Term Consistency Is Key

Bristol-Myers

Eli Lilly

Walgreens

To say that hedge fund and mutual fund managers tend to follow the herd is an incredible understatement and always has been.

Fund Managers Pile Into Big Dividend Health Care Stocks: 8 ‘Strong Buy' Winners

Amgen Inc. (AMGN) Management Presents at Oppenheimer's 32nd Annual Healthcare Conference 2022 (Transcript)

There are reasons to like Amgen that go beyond its market-beating 3.4% dividend yield.

1 Great Income Stock to Buy and Hold Forever

Intel

Stocks have been pounded all year long, and many of those taking the biggest hit are in the Nasdaq composite index, which as of Friday's close was officially in bear market territory.

5 ‘Strong Buy' Nasdaq Stocks That Also Pay the Biggest Dividends in the Index

Adagene

Checkmate Pharmaceuticals

Gritstone Oncology Inc

Given that developing biotechnology companies are more susceptible to swings in stock price than established ones, investors might want to keep an eye on happenings at next month's American Association for Cancer Research Annual Meeting in New Orleans. Of the eight public companies that will discuss clinical trial results, half qualify as small caps or lesser.

Investors Hoping for News at Cancer Meeting That Will Boost Share Prices

THOUSAND OAKS, Calif., March 10, 2022 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will virtually present at the 32nd Annual Oppenheimer Healthcare Conference at 11:20 a.m.

Amgen To Present At The 32nd annual Oppenheimer Healthcare Conference

Which pharmaceutical companies can rocket your portfolio right now? Let's take a look.

3 Dividend-Paying Pharmaceutical Stocks You Can't Ignore

Amgen (AMGN) reported earnings 30 days ago. What's next for the stock?

Amgen (AMGN) Down 4.1% Since Last Earnings Report: Can It Rebound?

American Tower

Blackstone Group

Comcast

Morgan Stanley

If you're a long-term investor you need top-quality dividend stocks in your portfolio. That doesn't mean big yields as much as reliable ones.

7 Dividend Stocks to Finance Your Golden Years

News for Amgen Stock (AMGN)